Please use this identifier to cite or link to this item: http://repositorio.ufpa.br/jspui/handle/2011/6868
Compartilhar:
Type: Artigo de Periódico
Issue Date: 2014
Authors: DORNELLES, Alicia Dorneles
PINTO, Louise Lapagesse de Carmargo
PAULA, Ana Carolina de
STEINER, Carlos Eduardo
LOURENÇO, Charles Marques
KIM, Chong Ae
HOROVITZ, Dafne Dain Gandelman
RIBEIRO, Erlane Marques
VALADARES, Eugênia Ribeiro
GOULART, Isabela
SOUZA, Isabel Cristina Neves de
NERI, João Ivanildo da Costa Ferreira
SILVA, Luiz Carlos Santana da
SILVA, Luiz Roberto
RIBEIRO, Márcia Gonçalves
OLIVEIRA SOBRINHO, Ruy Pires de
GIUGLIANI, Roberto
SCHWARTZ, Ida Vanessa Doederlein
Title: Enzyme replacement therapy for Mucopolysaccharidosis Type I among patients followed within the MPS Brazil Network
Citation: DORNELLES, Alícia Dorneles et al. Enzyme replacement therapy for Mucopolysaccharidosis Type I among patients followed within the MPS Brazil Network. Genetics and Molecular Biology, Ribeirão Preto, v. 37, n. 1, p. 23-29, 2014. Disponível em: <http://www.scielo.br/pdf/gmb/v37n1/a06v37n1.pdf>. Acesso em: 25 ago. 2015. <http://dx.doi.org/10.1590/S1415-47572014000100006>.
Abstract: Mucopolysaccharidosis type I (MPS I) is a rare lysosomal disorder caused by deficiency of alpha-L-iduronidase. Few clinical trials have assessed the effect of enzyme replacement therapy (ERT) for this condition. We conducted an exploratory, open-label, non-randomized, multicenter cohort study of patients with MPS I. Data were collected from questionnaires completed by attending physicians at the time of diagnosis (T1; n = 34) and at a median time of 2.5 years later (T2; n = 24/34). The 24 patients for whom data were available at T2 were allocated into groups: A, no ERT (9 patients; median age at T1 = 36 months; 6 with severe phenotype); B, on ERT (15 patients; median age at T1 = 33 months; 4 with severe phenotype). For all variables in which there was no between-group difference at baseline, a delta of ≥ ± 20% was considered clinically relevant. The following clinically relevant differences were identified in group B in T2: lower rates of mortality and reported hospitalization for respiratory infection; lower frequency of hepatosplenomegaly; increased reported rates of obstructive sleep apnea syndrome and hearing loss; and stabilization of gibbus deformity. These changes could be due to the effect of ERT or of other therapies which have also been found more frequently in group B. Our findings suggest MPS I patients on ERT also receive a better overall care. ERT may have a positive effect on respiratory morbidity and overall mortality in patients with MPS I. Additional studies focusing on these outcomes and on other therapies should be performed.
Keywords: Terapia de reposição enzimática
Laronidase
Mucopolissacaridose tipo 1
Alph-L-eduronidase
ISSN: 1415-4757
Appears in Collections:Artigos Científicos - HUBFS
Artigos Científicos - ICB

Files in This Item:
File Description SizeFormat 
Artigo_EnzymeReplacementTherapy.pdf456,07 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons